Pharma industry interest in NICE/MHRA parallel advice still limited but UK early access scheme 'could foster use'
This article was originally published in SRA
Executive Summary
Demand by drug companies for the parallel scientific advice scheme that UK health technology assessment body NICE has in place with the Medicines and Healthcare Products Regulatory Agency has been extremely limited to date. Nonetheless, NICE considers the joint advice "a good opportunity for a detailed engagement on both regulatory and HTA issues and evidence requirements" and says there could be added interest soon.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.